000148412 001__ 148412
000148412 005__ 20240229123032.0
000148412 0247_ $$2doi$$a10.1002/1878-0261.12611
000148412 0247_ $$2pmid$$apmid:31816156
000148412 0247_ $$2ISSN$$a1574-7891
000148412 0247_ $$2ISSN$$a1878-0261
000148412 0247_ $$2altmetric$$aaltmetric:76418085
000148412 037__ $$aDKFZ-2019-02967
000148412 041__ $$aeng
000148412 082__ $$a610
000148412 1001_ $$0P:(DE-He78)9b2a61b2abe4a64ca23b6783b7c4fe63$$aAlwers, Elizabeth$$b0$$eFirst author$$udkfz
000148412 245__ $$aMicrosatellite instability and survival after adjuvant chemotherapy among stage II and III colon cancer patients: results from a population-based study.
000148412 260__ $$aHoboken, NJ$$bJohn Wiley & Sons, Inc.$$c2020
000148412 3367_ $$2DRIVER$$aarticle
000148412 3367_ $$2DataCite$$aOutput Types/Journal article
000148412 3367_ $$0PUB:(DE-HGF)16$$2PUB:(DE-HGF)$$aJournal Article$$bjournal$$mjournal$$s1601364415_28271
000148412 3367_ $$2BibTeX$$aARTICLE
000148412 3367_ $$2ORCID$$aJOURNAL_ARTICLE
000148412 3367_ $$00$$2EndNote$$aJournal Article
000148412 500__ $$a#EA:C070#LA:C070# 14 (2), 363-372Feb 2020
000148412 520__ $$aPrevious studies have reported conflicting results regarding the benefit of administering 5-FU based chemotherapy to colon cancer patients with microsatellite instable (MSI-high) tumors, and results from stage-specific analyses are scarce. Patients with stage II or III colon cancer were recruited as part of a population-based study between 2003 and 2015. Cox regression models including propensity-score weighting were used to calculate hazard ratios and confidence intervals for the association between chemotherapy and cancer-specific (CSS), relapse-free (RFS) and overall survival (OS) by stage of disease and MSI status of the tumor. Median follow-up was 6.2 years. A total of 1010 colon cancer patients were included in the analysis (54% stage II, 46% stage III, 20% MSI-high). Adjuvant chemotherapy was administered to 48 (8.7%) stage II and 366 (79%) stage III patients. Overall, patients who received adjuvant chemotherapy had better CSS (HR = 0.65[0.49-0.86]) than those who received surgery alone. Among stage II patients, only 64 (12%) cancer-related deaths occurred, none of which in MSI-high patients who received chemotherapy. Patients with MSI-high tumors who received adjuvant treatment showed better CSS and a tendency towards better RFS compared to MSI-high patients who did not receive chemotherapy (HRCSS  = 0.36[0.15-0.82], HRRFS  = 0.49[0.22-1.06]). Patients with microsatellite stable (MSS) tumors receiving adjuvant chemotherapy also had significantly better survival (HRCSS  = 0.65[0.48-0.87] and HRRFS  = 0.68[0.52-0.88]). In this population-based study including stage II and III colon cancer patients, we observed a survival benefit of adjuvant chemotherapy for both MSS and MSI-high tumors. Adjuvant chemotherapy seemed to be beneficial among high-risk stage II patients with MSI-high tumors.
000148412 536__ $$0G:(DE-HGF)POF3-313$$a313 - Cancer risk factors and prevention (POF3-313)$$cPOF3-313$$fPOF III$$x0
000148412 588__ $$aDataset connected to CrossRef, PubMed,
000148412 7001_ $$0P:(DE-He78)bbfe0ebad1e3b608bca2b49d4f86bd09$$aJansen, Lina$$b1$$udkfz
000148412 7001_ $$aBläker, Hendrik$$b2
000148412 7001_ $$aKloor, Matthias$$b3
000148412 7001_ $$aTagscherer, Katrin E$$b4
000148412 7001_ $$aRoth, Wilfried$$b5
000148412 7001_ $$0P:(DE-He78)657300dfd28903ec8149ca9bf5e7968d$$aBoakye, Daniel$$b6$$udkfz
000148412 7001_ $$aHerpel, Esther$$b7
000148412 7001_ $$aGrüllich, Carsten$$b8
000148412 7001_ $$0P:(DE-He78)c259d6cc99edf5c7bc7ce22c7f87c253$$aChang-Claude, Jenny$$b9$$udkfz
000148412 7001_ $$0P:(DE-He78)90d5535ff896e70eed81f4a4f6f22ae2$$aBrenner, Hermann$$b10$$udkfz
000148412 7001_ $$0P:(DE-He78)6c5d058b7552d071a7fa4c5e943fff0f$$aHoffmeister, Michael$$b11$$eLast author$$udkfz
000148412 773__ $$0PERI:(DE-600)2322586-5$$a10.1002/1878-0261.12611$$gp. 1878-0261.12611$$n2$$p363-372$$tMolecular oncology$$v14$$x1878-0261$$y2020
000148412 909CO $$ooai:inrepo02.dkfz.de:148412$$pVDB
000148412 9101_ $$0I:(DE-588b)2036810-0$$6P:(DE-He78)9b2a61b2abe4a64ca23b6783b7c4fe63$$aDeutsches Krebsforschungszentrum$$b0$$kDKFZ
000148412 9101_ $$0I:(DE-588b)2036810-0$$6P:(DE-He78)bbfe0ebad1e3b608bca2b49d4f86bd09$$aDeutsches Krebsforschungszentrum$$b1$$kDKFZ
000148412 9101_ $$0I:(DE-588b)2036810-0$$6P:(DE-He78)657300dfd28903ec8149ca9bf5e7968d$$aDeutsches Krebsforschungszentrum$$b6$$kDKFZ
000148412 9101_ $$0I:(DE-588b)2036810-0$$6P:(DE-He78)c259d6cc99edf5c7bc7ce22c7f87c253$$aDeutsches Krebsforschungszentrum$$b9$$kDKFZ
000148412 9101_ $$0I:(DE-588b)2036810-0$$6P:(DE-He78)90d5535ff896e70eed81f4a4f6f22ae2$$aDeutsches Krebsforschungszentrum$$b10$$kDKFZ
000148412 9101_ $$0I:(DE-588b)2036810-0$$6P:(DE-He78)6c5d058b7552d071a7fa4c5e943fff0f$$aDeutsches Krebsforschungszentrum$$b11$$kDKFZ
000148412 9131_ $$0G:(DE-HGF)POF3-313$$1G:(DE-HGF)POF3-310$$2G:(DE-HGF)POF3-300$$3G:(DE-HGF)POF3$$4G:(DE-HGF)POF$$aDE-HGF$$bGesundheit$$lKrebsforschung$$vCancer risk factors and prevention$$x0
000148412 9141_ $$y2020
000148412 915__ $$0StatID:(DE-HGF)0100$$2StatID$$aJCR$$bMOL ONCOL : 2017
000148412 915__ $$0StatID:(DE-HGF)0200$$2StatID$$aDBCoverage$$bSCOPUS
000148412 915__ $$0StatID:(DE-HGF)0300$$2StatID$$aDBCoverage$$bMedline
000148412 915__ $$0StatID:(DE-HGF)0310$$2StatID$$aDBCoverage$$bNCBI Molecular Biology Database
000148412 915__ $$0StatID:(DE-HGF)0320$$2StatID$$aDBCoverage$$bPubMed Central
000148412 915__ $$0StatID:(DE-HGF)0501$$2StatID$$aDBCoverage$$bDOAJ Seal
000148412 915__ $$0StatID:(DE-HGF)0500$$2StatID$$aDBCoverage$$bDOAJ
000148412 915__ $$0StatID:(DE-HGF)0030$$2StatID$$aPeer Review$$bDOAJ : Peer review
000148412 915__ $$0LIC:(DE-HGF)CCBYNV$$2V:(DE-HGF)$$aCreative Commons Attribution CC BY (No Version)$$bDOAJ
000148412 915__ $$0StatID:(DE-HGF)0199$$2StatID$$aDBCoverage$$bClarivate Analytics Master Journal List
000148412 915__ $$0StatID:(DE-HGF)0111$$2StatID$$aWoS$$bScience Citation Index Expanded
000148412 915__ $$0StatID:(DE-HGF)0150$$2StatID$$aDBCoverage$$bWeb of Science Core Collection
000148412 915__ $$0StatID:(DE-HGF)1050$$2StatID$$aDBCoverage$$bBIOSIS Previews
000148412 915__ $$0StatID:(DE-HGF)9905$$2StatID$$aIF >= 5$$bMOL ONCOL : 2017
000148412 9202_ $$0I:(DE-He78)C070-20160331$$kC070$$lC070 Klinische Epidemiologie und Alternf.$$x0
000148412 9200_ $$0I:(DE-He78)C070-20160331$$kC070$$lC070 Klinische Epidemiologie und Alternf.$$x0
000148412 9201_ $$0I:(DE-He78)C070-20160331$$kC070$$lC070 Klinische Epidemiologie und Alternf.$$x0
000148412 9201_ $$0I:(DE-He78)C020-20160331$$kC020$$lC020 Epidemiologie von Krebs$$x1
000148412 9201_ $$0I:(DE-He78)C120-20160331$$kC120$$lPräventive Onkologie$$x2
000148412 9201_ $$0I:(DE-He78)HD01-20160331$$kHD01$$lDKTK HD zentral$$x3
000148412 980__ $$ajournal
000148412 980__ $$aVDB
000148412 980__ $$aI:(DE-He78)C070-20160331
000148412 980__ $$aI:(DE-He78)C020-20160331
000148412 980__ $$aI:(DE-He78)C120-20160331
000148412 980__ $$aI:(DE-He78)HD01-20160331
000148412 980__ $$aUNRESTRICTED